Introduction
The coronavirus disease 2019 (COVID-19) first outbreak at the end of
2019 in Wuhan, China, and quickly spread into more than 200 countries
worldwide, turning into a global pandemic. As a new emerging and severe
contagious disease, all people are vulnerable to it. Therefore, it’s not
surprising that more and more pregnant patients are being
reported.1,
2 The maternal and fetus outcomes of
COVID-19 pregnant women are the focus of our attention. Fortunately,
based on the results of current studies, the clinical characteristic and
outcomes of COVID-19 maternal patients are similar to that of
non-pregnant women. No maternal death has been
reported.1,
2 But the consequences of infection with
SARS-CoV-2 for fetus or newborn are uncertain; especially, there is
still huge controversy regarding whether SARS-CoV-2 can be
transplacentally transmitted from infected pregnant women to their
fetuses. A previous review, through analyzing a total of 38 pregnant
women with COVID-19 in China, didn’t found intrauterine transmission of
SARS-CoV-2.2 However, a
recent study by L Dong et
al3 described a newborn
born to a COVID-19 mother with elevated IgM antibody level to
SARS-CoV-2, indicating a possible transplacental transmission.
Here, we reported a newborn born to a convalescent COVID-19 mother has a
viral pneumonia on the day of birth and elevated IgM/IgG antibody levels
to SARS-CoV-2 at 3 days age.